The Center for Innovative Phage Applications and Therapeutics (IPATH) was founded in the UC San Diego School of Medicine in June 2018 with seed funding from UC San Diego Chancellor Pradeep Khosla. Our goal is to pursue, through collaboration with researchers, companies and institutions around the world, new treatments for combating antimicrobial resistant diseases—focusing on bacteriophage (phage) therapy. We have treated and will continue to treat patients with life-threatening multi-drug resistant infections with phage therapy through the FDA’s compassionate use program. We also strive to advance phage therapy into clinical trials so that it can be rigorously evaluated and if proven efficacious, become more widely available to combat the global superbug crisis. The first planned clinical trial will focus on cystic fibrosis patients who are shedding Pseudomonas aeruginosa.
Official Web Site of the University of California, San Diego.